The promise of cell and gene therapies will be realized when patient access becomes more commonplace. In studies, 9 out of 10 people with acute lymphoblastic leukemia whose cancer didn't respond to other treatments or whose cancer came back had full remission with CAR T-cell therapy. How do we prepare for a future where CAR-T is a first line therapy for indications that affect broad patient groups? Watch the discussion on Distributed and Point-of-Care Manufacturing – Building Infrastructure and Capacity below with Carol Houts, Edwin Stone, and Krisha Patel.